AbbVie Inc. $ABBV Shares Sold by SYM FINANCIAL Corp

SYM FINANCIAL Corp lowered its position in AbbVie Inc. (NYSE:ABBV) by 43.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,405 shares of the company’s stock after selling 3,345 shares during the quarter. SYM FINANCIAL Corp’s holdings in AbbVie were worth $1,020,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Evolution Wealth Management Inc. purchased a new position in AbbVie during the 2nd quarter worth $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the second quarter worth about $36,000. Bear Mountain Capital Inc. grew its holdings in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new position in AbbVie in the 2nd quarter valued at about $39,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie Stock Performance

AbbVie stock opened at $220.42 on Friday. The company has a market cap of $389.56 billion, a P/E ratio of 166.98, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The business has a fifty day moving average of $224.67 and a two-hundred day moving average of $218.02.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $249.37.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.